Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Meng Lv, Hao Jiang, Yuhua Li, Yicheng Zhang, Jie Jin, Hongsheng Zhou, Kailin Xu, Mingfeng Zhao, Xin Du, Kai Hu, Jun Hu, Jinghua Zhao, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2025-1563

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Blood (2025) 146 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2025-6865

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Fen Zhou, Yuhua Li, Ying Wang, Xi Zhang, Jianmin Yang, Xiaobing Huang, JIN WANG, Xianmin Song, Xinsheng Xie, Li Wang, Jie Jin, Liye Zhong, Aibin Liang, Zhenyang Gu, Shengli Xue, Er-Lie Jiang, Baohong Ping, Heng Mei

Blood (2025) 146 (Supplement 1): 6859.

https://doi.org/10.1182/blood-2025-6859

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Blood (2025) 146 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2025-6855

Published: 2025

Journal Articles

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Sanfang Tu, Kaixin Ou, Lei Wang, Xuan Zhou, Chaoyang Song, Shaojie Wu, Rui Huang, Yanjie He, Yuxian Huang, Chunyan Yue, Minhong Huang, Yuhua Li

Blood (2025) 146 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2025-3353

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Sanfang Tu, Minhong Huang, Chaoyang Song, Yuxian Huang, Rui Huang, Yanjie He, Shaojie Wu, Xuan Zhou, Jilong Yang, Chunyan Yue, Lei Wang, Yuhua Li

Blood (2025) 146 (Supplement 1): 7754.

https://doi.org/10.1182/blood-2025-7754

Published: 2025

Journal Articles

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2025-5245

Published: 2025

Journal Articles

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Sanfang Tu, Langqi Wang, Shaojie Wu, Yanjie He, Chaoyang Song, Zhao Liang, Xuan Zhou, Lei Wang, Chunyan Yue, Lijuan Zhou, Jilong Yang, Yuhua Li

Blood (2025) 146 (Supplement 1): 8045.

https://doi.org/10.1182/blood-2025-8045

Published: 2025

Journal Articles

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

Yuxian Huang, Yingzhi He, Jiayue Wei, Ziwei Liu, Yinjie Qin, Yeqin Zheng, Yuchang Lin, Zhiming Li, Yuhua Li

Blood (2025) 146 (Supplement 1): 7794.

https://doi.org/10.1182/blood-2025-7794

Published: 2025

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Blood (2025) 146 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2025-5209

Published: 2025

Journal Articles

Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis.

Yuxian Huang, Ziwei Liu, Jiayue Wei, Yinjie Qin, Yingzhi He, Yeqin Zheng, Yuchang Lin, Zhiming Li, Yuhua Li

Blood (2025) 146 (Supplement 1): 7177.

https://doi.org/10.1182/blood-2025-7177

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Shaojie Wu, Yanni Deng, Mingyao Lai, Sanfang Tu, Linbo Cai, Yuhua Li

Blood (2024) 144 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2024-200645

Published: 2024

Journal Articles

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Shaojie Wu, Junru Du, Jie Ma, Li Huang, Zhiqiang Peng, Yiwen Ling, Xiaofang Deng, Weijian Zhu, Hongliang Li, Hua Wang, Yuhua Li

Blood (2024) 144 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2024-200667

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis.

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only